Publications
184
Citations
2,356
Est. group size
~3
Recurring co-author estimate
Active years
25
Publishing since 2002
Niranjan Awasthi studies cancers of the digestive system, especially pancreatic, gastric, and bile-duct (cholangiocarcinoma) tumors. Much of the work tests whether adding targeted drugs\u2014such as inhibitors of specific tumor-signaling proteins or of blood-vessel growth (angiogenesis)\u2014can make standard chemotherapy more effective in laboratory and preclinical animal models. The goal is to identify drug combinations that shrink tumors and slow their spread.
Publication activity has been variable across the decade, with a very large spike in 2023 and steady output in most other years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~6 · 5% small-team papers (≤3 authors) · across 16 venues
- Abstract 3053: SHP2 inhibition with RMC4630 demonstrates antitumor efficacy and potentiates nanoparticle-paclitaxel response in pancreatic cancer
Cancer Research · 2025
- Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models
Journal of Cellular and Molecular Medicine · 2024
- Supplementary Figure from A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis
2023
- Supplementary Figure from A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis
2023
- Data from A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis
2023
- Data from A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis
2023
- Data from PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer
2023
- Supplementary Figure 1 from PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer
2023
- Supplementary Figure 1 from PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer
2023
- Data from PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer
2023
- Liver Cirrhosis
Anusandhaan - Vigyaan Shodh Patrika · 2023
- Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models
Frontiers in Oncology · 2023
- Data from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
2023
- Data from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
2023
- Supplementary Figure 1 from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
2023
- Cancer Research×28
- Journal of Clinical Oncology×4
- PMC×4
- Journal of Cellular and Molecular Medicine×3
- Molecular Cancer Therapeutics×3
- Margaret A. Schwarz
Medicine · Indiana University
- Mark Bloomston
Medicine · The Ohio State University
- Patrick L. Quinn
Medicine · The Ohio State University
- Clifford S. Cho
Medicine · University of Michigan
- Carl Schmidt
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile